Imunon, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Max Link. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Max Link has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AMDA / Amedica Corporation Director 77,069
Director 15,000
US:CLSN / Imunon Inc Director 109,162
US:US00C4W1JQ50 / Alexion Pharmaceuticals, Inc. Director 2,785
US:CYTR / LadRx Corp Director 180,000
US:DSCO / Discovery Laboratories, Inc. Director 60,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Max Link. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IMNN / Imunon, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMNN / Imunon, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-12-10 CLSN LINK MAX 14,000 7.6000 966 110.2000 106,400 36 631.125 502,636 472.40
2007-02-27 CLN LINK MAX 10,000 3.4937 10,000 3.4937 34,937
2007-02-26 CLN LINK MAX 10,000 3.5027 10,000 3.5027 35,027
2005-05-24 CLN LINK MAX 55,700 0.4140 55,700 0.4140 23,060
2005-05-23 CLN LINK MAX 44,300 0.4005 44,300 0.4005 17,742

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMNN / Imunon, Inc. Insider Trades
Insider Sales IMNN / Imunon, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMNN / Imunon, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMNN / Imunon, Inc. Insider Trades
Insider Purchases LADX / LadRx Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMNN / Imunon, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-02-23 CYTR LINK MAX 136,540 0.3265 22,757 1.9590 44,580 134 5.43 78,985 177.18
2012-02-22 CYTR LINK MAX 68,789 0.3093 11,465 1.8558 21,276

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LADX / LadRx Corporation Insider Trades
Insider Sales LADX / LadRx Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMNN / Imunon, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LADX / LadRx Corporation Insider Trades
Insider Purchases SINT / Sintx Technologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMNN / Imunon, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SINT / Sintx Technologies, Inc. Insider Trades
Insider Sales SINT / Sintx Technologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMNN / Imunon, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SINT / Sintx Technologies, Inc. Insider Trades
Insider Purchases WINTW / Windtree Therapeutics, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMNN / Imunon, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WINTW / Windtree Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Sales WINTW / Windtree Therapeutics, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMNN / Imunon, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WINTW / Windtree Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Max Link as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2014-08-14 2014-08-12 4 AMDA AMEDICA Corp
Common Stock
A - Award 6,984 77,069 9.97
2014-08-05 2014-08-04 4 BSTC BIOSPECIFICS TECHNOLOGIES CORP
Stock Option (Right to Buy)
A - Award 15,000 15,000
2014-06-24 2014-06-20 4 CLSN Celsion CORP
Option to Purchase Celsion Corporation Common Stock
A - Award 40,000 109,162 57.84
2014-05-07 2014-05-05 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
A - Award 2,785 2,785 159.70 444,764 444,764
2014-03-04 2014-02-28 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock
A - Award 895 59,469 1.53
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Series F Preferred Stock
C - Conversion -125,000 0 -100.00
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Series E Preferred Stock
C - Conversion -25,000 0 -100.00
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Series D Preferred Stock
C - Conversion -35,000 0 -100.00
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Series C Preferred Stock
C - Conversion -100,000 0 -100.00
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Series A-1 Preferred Stock
C - Conversion -333,334 0 -100.00
2014-02-21 2014-02-19 4 AMDA AMEDICA Corp
Common Stock
C - Conversion 57,864 70,666 451.99
2014-02-12 2014-02-11 4 CLSN Celsion CORP
Option to Purchase Celsion Corporation Common Stock
A - Award 14,000 69,162 25.38
2014-02-12 3 AMDA AMEDICA Corp
Common Stock
25,604
2014-02-12 3 AMDA AMEDICA Corp
Common Stock
25,604
2014-02-05 2014-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -3,000 58,574 -4.87 157.09 -471,270 9,201,390
2014-02-05 2014-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -13,912 61,574 -18.43 155.91 -2,169,020 9,600,002
2014-02-05 2014-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -10,662 75,486 -12.38 154.95 -1,652,077 11,696,556
2014-02-05 2014-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -12,426 86,148 -12.61 154.02 -1,913,853 13,268,515
2013-12-12 2013-12-10 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 180,000 180,000
2013-05-09 2013-05-07 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
A - Award 3,425 3,425
2013-05-08 2013-05-06 4 CLSN Celsion CORP
Option to Purchase Celsion Corporation Common Stock
A - Award 45,000 248,245 22.14
2013-02-08 2013-02-06 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
A - Award 2,471 98,574 2.57
2012-12-11 2012-12-10 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 100,000 100,000
2012-12-11 2012-12-10 4 CLSN Celsion CORP
Celsion Corporation Common Stock
P - Purchase 14,000 380,385 3.82 7.60 106,400 2,890,926
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Warrants to purchase Celsion Corporation Common Stock
X - Other -18,735 0 -100.00 4.22 -79,062
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Warrants to purchase Celsion Corporation Common Stock
X - Other -34,542 18,735 -64.83 2.77 -95,681 51,896
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Warrants to purchase Celsion Corporation Common Stock
X - Other -17,083 53,277 -24.28 3.25 -55,520 173,150
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Celsion Corporation Common Stock
M - Exercise 18,735 366,385 5.39 4.22 79,062 1,546,145
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Celsion Corporation Common Stock
M - Exercise 34,542 347,650 11.03 2.77 95,681 962,990
2012-09-21 2012-09-20 4 CLSN Celsion CORP
Celsion Corporation Common Stock
M - Exercise 17,083 313,108 5.77 3.25 55,520 1,017,601
2012-09-20 2012-09-20 4 CLSN Celsion CORP
Option to purchase Celsion Corporation Common Stock
X - Other -35,000 219,911 -13.73 2.72 -95,200 598,158
2012-09-20 2012-09-20 4 CLSN Celsion CORP
Celsion Corporation Common Stock
M - Exercise 35,000 296,025 13.41 2.72 95,200 805,188
2012-08-28 2012-08-24 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -40,000 0 -100.00
2012-08-28 2012-08-24 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -40,000 0 -100.00
2012-08-28 2012-08-24 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 40,000 169,781 30.82 18.01 720,400 3,057,756
2012-08-28 2012-08-24 4 ALXN ALEXION PHARMACEUTICALS INC
Common stock, par value $.0001 per share
M - Exercise 40,000 129,781 44.55 10.84 433,600 1,406,826
2012-08-15 2012-08-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -27,446 89,781 -23.41 104.24 -2,860,971 9,358,771
2012-08-15 2012-08-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -72,227 117,227 -38.12 103.76 -7,494,274 12,163,474
2012-06-12 2012-06-08 4 DSCO DISCOVERY LABORATORIES INC /DE/
Non-Qualified Stock Option (right to buy)
A - Award 60,000 60,000
2012-05-15 2012-05-14 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 50,000 50,000
2012-05-09 2012-05-08 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
A - Award 3,237 3,237
2012-02-24 2012-02-23 4 CYTR CYTRX CORP
Common Stock
P - Purchase 136,540 260,305 110.32 0.33 44,580 84,990
2012-02-24 2012-02-22 4 CYTR CYTRX CORP
Common Stock
P - Purchase 68,789 123,765 125.13 0.31 21,276 38,281
2012-02-24 2012-02-22 4 CLSN Celsion CORP
Option to purchase Celsion Corporation Common Stock
A - Award 35,000 254,911 15.92
2012-02-06 2012-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 3,115 96,103 3.35
2007-03-01 2007-02-27 4 CLN CELSION CORP
Common Stock
P - Purchase 10,000 97,466 11.43 3.49 34,937 340,517
2007-02-27 2007-02-26 4 CLN CELSION CORP
Common Stock
P - Purchase 10,000 87,466 12.91 3.50 35,027 306,367
2005-05-25 2005-05-24 4 CLN CELSION CORP
Common Stock
P - Purchase 55,700 720,095 8.38 0.41 23,060 298,119
2005-05-25 2005-05-23 4 CLN CELSION CORP
Common Stock
P - Purchase 44,300 664,395 7.14 0.40 17,742 266,090
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)